Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.55 |
| ▸ | NCF1 | P14598 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 4/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2957741 | 0.99 | ADRB2 (0.54) | ADRB2NCF1HTR2CHTR3AHTR1D | |
| SCHEMBL2966951 | 0.81 | MAPT (0.48) | HTR3AMAPTTHRBHTR1ATP53 | |
| Hydrochloric Acid SCHEMBL6220144 | 0.80 | MAPT (0.47) | HTR3AMAPTTHRBHTR1ATP53 | |
| SCHEMBL7828988 | 0.78 | ADRB2 (0.52) | ADRB2NCF1HTR2CHTR3AHTR3E | |
| SCHEMBL2968890 | 0.77 | MAPT (0.50) | NCF1HTR3AHTR1DMAPTTHRB | |
| SCHEMBL4307891 | 0.75 | DRD4 (0.46) | SIGMAR1MAPTTP53 | |
| SCHEMBL13809829 | 0.75 | KDM4E (0.39) | ADRB2NCF1MAPTTP53LMNA | |
| SCHEMBL4303438 | 0.75 | KDM4E (0.39) | ADRB2NCF1MAPTTP53LMNA | |
| Hydrochloric Acid SCHEMBL4307355 | 0.74 | DRD4 (0.46) | ALDH1A1SIGMAR1MAPTTP53LMNA | |
| SCHEMBL4310830 | 0.74 | DRD4 (0.46) | SIGMAR1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1935887-B1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | AVENTIS PHARMACEUTICAL INC. (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1392676-A2 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| US-20030229066-A1 | Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. | 2003-12-11 | — | — | US | disclosed |
| EP-1361875-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362039-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066468-A2 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066469-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRB2 267/4885NCF1 3846/4885HTR2C 21/4885 |
| US-20030229066-A1 | Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRB2 295/4885NCF1 3806/4885HTR2C 20/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRB2 261/4885NCF1 3941/4885HTR2C 22/4885 |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | DRD3, DRD2, DRD1 | ADRB2 320/4885NCF1 3742/4885HTR2C 16/4885 |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | DRD3, DRD2, HTR3C | ADRB2 349/4885NCF1 3764/4885HTR2C 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.